<DOC>
	<DOC>NCT00545012</DOC>
	<brief_summary>This long-term open label follow-up trial gave pediatric subjects suffering from typical absences in CAE or JAE the opportunity to continue levetiracetam treatment after participation in the pilot study (study N162) or the double-blind study (study N163). Safety and efficacy data were obtained.</brief_summary>
	<brief_title>A Safety and Efficacy Follow-up Study With Levetiracetam in Children (4-17 Years Old) Suffering From Absence Seizures</brief_title>
	<detailed_description />
	<mesh_term>Seizures</mesh_term>
	<mesh_term>Epilepsy, Absence</mesh_term>
	<mesh_term>Etiracetam</mesh_term>
	<mesh_term>Piracetam</mesh_term>
	<criteria>Male/female 417 years old having participated in study N162 or in study N163 suffering from typical absences with 3 Hz spikewave discharges, with or without tonicclonic seizures, in CAE or JAE expected reasonable benefit (efficacy and tolerability) of levetiracetam long term administration allergy/intolerance to pyrrolidine derivatives and/or excipients use of &gt; 2 concomitant antiepileptic treatment or valproate, ethosuximide or lamotrigine</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>Levetiracetam</keyword>
	<keyword>Keppra</keyword>
</DOC>